Cargando…

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: We aimed to evaluate the impact of therapeutic modifications of atezolizumab (Atezo) plus bevacizumab (Bev) therapy (Atezo/Bev) in the case of intolerable adverse events on the prognosis of patients with unresectable hepatocellular carcinoma. Therapeutic modifications included the in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokunaga, Takayuki, Tateyama, Masakuni, Kondo, Yasuteru, Miuma, Satoshi, Miyase, Shiho, Tanaka, Kentaro, Narahara, Satoshi, Inada, Hiroki, Kurano, Sotaro, Yoshimaru, Yoko, Nagaoka, Katsuya, Watanabe, Takehisa, Setoyama, Hiroko, Fukubayashi, Kotaro, Tanaka, Motohiko, Tanaka, Yasuhito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001232/ https://www.ncbi.nlm.nih.gov/pubmed/36900359 http://dx.doi.org/10.3390/cancers15051568

Ejemplares similares

Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study
por: Tateyama, Masakuni, et al.
Publicado: (2020)

Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma
por: Narahara, Satoshi, et al.
Publicado: (2021)

Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method
por: Fukubayashi, Kotaro, et al.
Publicado: (2015)

Oral branched-chain amino acid granules improve structure and function of human serum albumin in cirrhotic patients
por: Setoyama, Hiroko, et al.
Publicado: (2016)

Clinical usefulness of inside stents in anastomotic biliary strictures after liver transplantation
por: Kugiyama, Naotaka, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
por: Mitsuyama, Yasuhito, et al.
Publicado: (2023)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021)

Comparison of endoscopic submucosal resection with ligation and endoscopic submucosal dissection for small rectal neuroendocrine tumors: A multicenter retrospective study
por: Matsuno, Kenshi, et al.
Publicado: (2022)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
por: Tomonari, Tetsu, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Niizeki, Takashi, et al.
Publicado: (2022)

Possible Association of Mutations in the MEFV Gene with the Intestinal Phenotype of Behçet’s Disease and Refractoriness to Treatment
por: Furuta, Yoki, et al.
Publicado: (2023)

Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins
por: Hayashi, Sanae, et al.
Publicado: (2021)

Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
por: Tanaka, Takashi, et al.
Publicado: (2022)

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Matsumoto, Hiroaki, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Risk stratification for advanced colorectal neoplasia based on the findings of the index and first surveillance colonoscopies
por: Honda, Munenori, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
por: Sugimoto, Rie, et al.
Publicado: (2022)

Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B
por: Watanabe, Takehisa, et al.
Publicado: (2021)

Drug Discovery Study Aimed at a Functional Cure for HBV
por: Watanabe, Takehisa, et al.
Publicado: (2022)

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
por: Inoue, Takako, et al.
Publicado: (2023)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
por: Tsunemitsu, Ryosuke, et al.
Publicado: (2023)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Mixed Neuroendocrine Non-Neuroendocrine Neoplasm Arising in the Ectopic Gastric Mucosa of Esophagus
por: Gushima, Ryosuke, et al.
Publicado: (2022)

DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC
por: Kondo, Yasuteru, et al.
Publicado: (2022)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma
por: Alkharashi, Majed S., et al.
Publicado: (2023)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
por: Su, Dan, et al.
Publicado: (2021)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Kulkarni, Anand V., et al.
Publicado: (2023)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Comparison of compressive forces caused by various cannulated cancellous screws used in arthroscopic ankle arthrodesis
por: Kamijo, Satoshi, et al.
Publicado: (2017)

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
por: Rimini, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fg4rapmvsuvden5apn39m0hce5